Genentech Reports Results of Polivy (polatuzumab vedotin-piiq) + R-CHP in P-III POLARIX Trial for the Treatment of Diffuse Large B-Cell Lymphoma

Shots:

• The P-III POLARIX trial evaluates the efficacy, safety, and PK of Polivy + R-CHP vs R-CHOP in 879 patients in a ratio (1:1) with previously untreated DLBCL for 6 cycles, followed by Rituxan for 2cycles; or R-CHOP + Polivy PBO for 6 cycles, followed by 2 cycles of Rituxan. The trial is being conducted in collaboration with LYSA & LYSARC
• The trial met its 1EPs that demonstrating the improvement in PFS. Additionally, the safety results were consistent with previous trials. The results will be submitted to health authorities globally
• Polivy is currently used as an off-the-shelf, FD treatment option and approved in combination with bendamustine and Rituxan for R/R DLBCL in 60+ countries globally, including in the EU & US

Click here to­ read full press release/ article | Ref: Businesswire | Image: Xconomy